TY - JOUR
T1 - Proceedings from the 2ndNext Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
AU - NextGen 2019 Participants
AU - Canna, Scott W.
AU - Schulert, Grant S.
AU - De Jesus, Adriana
AU - Pickering, Alex
AU - Brunner, Hermine
AU - Gadina, Massimo
AU - Levine, Stewart
AU - Goldbach-Mansky, Raphaela
AU - Boutelle, Jonathan
AU - Sinha, Rashmi
AU - Debenedetti, Fabrizio
AU - Grom, Alexei
AU - Gottlieb, Beth
AU - Yeung, Rae
AU - Riskalla, Mona
AU - Prahalad, Sampath
AU - Alehashemi, Sara
AU - Chandrakasan, Shan
AU - Vastert, Bas
AU - Kimura, Yuki
AU - Carlson, Anna
AU - Schumacher, Emily
AU - Minerva, Regina
AU - Pierce, Jonathan
AU - Pierce, Kate
AU - Martinez, Zulayka
AU - Cupp, Kari
AU - Bush, Leah
AU - Costello, Wendy
AU - Delgaizo, Vincent
N1 - Publisher Copyright:
© 2020 The Author(s).
PY - 2020/7/15
Y1 - 2020/7/15
N2 - For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3-4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation (www.systemicjia.org/) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.
AB - For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3-4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation (www.systemicjia.org/) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.
KW - Alveolar macrophages
KW - Hemophagocytic lymphohistiocytosis
KW - Interferonopathy
KW - Interstitial lung disease
KW - Macrophage activation syndrome
KW - Pulmonary alveolar proteinosis
KW - Systemic juvenile idiopathic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85088030631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088030631&partnerID=8YFLogxK
U2 - 10.1186/s12969-020-00444-7
DO - 10.1186/s12969-020-00444-7
M3 - Article
C2 - 32664935
AN - SCOPUS:85088030631
SN - 1546-0096
VL - 18
JO - Pediatric Rheumatology
JF - Pediatric Rheumatology
M1 - 53
ER -